[ad_1]
The titles on Intersect ENT (NASDAQ: XENT) are rather positive Sunday, according to Accern .Accern identifies positive and negative press coverage by badyzing more than 20 million sources of blogs and news in Accern's real-time ranks companies on a scale ranging from negative to positive, with scores closest to one being the most favorable Intersect ENT scored 0.03 on the Accern Accern scale also gave the news articles about the medical equipment provider an impact score of 45.7094901211853 out of 100, indicating that recent media coverage is unlikely to have an impact on the price of the company's action in the coming days.
News headlines that may have influenced the badysis of Accern Sentiment Analysis:
Shares of Intersect ENT fell $ 1.35 at midday Friday, reaching $ 33.70. hands, compared to its average volume of 243,589. Intersect ENT has a 12-month low of $ 26.90 and a 12-month high of $ 42.95. The stock has a market capitalization of 1.02 billion, a price / earnings ratio of -60.18 and a beta of 0.77.
Intersect ENT (NASDAQ: XENT) has announced its results for the last time on Tuesday, May 1st. The medical equipment provider reported earnings per share of $ 0.21 for the quarter, compared with $ 0.02 for consensus badyst estimates ($ 0.23). Intersect ENT had a negative return on equity of 13.67% and a negative net margin of 15.73%. The company achieved a turnover of $ 24.70 million during the quarter, compared with $ 23.66 million for badysts. During the same period last year, the company posted earnings per share of $ 0.23. Intersect ENT revenues for the quarter increased 20.5% from one year to the next. Equity research badysts expect Intersect ENT to post earnings per share of -0.63 for the current year.
A number of badysts have published reports on the company. BTIG Research confirmed a "hold" rating on Intersect shares in a research note on Wednesday, May 2nd. BidaskClub has updated Intersect ENT from a "hold" note to a "buy" note in a report on Thursday, March 22nd. ValuEngine upgraded Intersect ENT from a "hold" rating to a "buy" rating in a report on Monday, April 2nd. JPMorgan Chase & Co. reiterated an "overweight" and set a price target of $ 48.00 on the shares of Intersect ENT in a report released on Wednesday, May 2. Finally, Berenberg Bank began covering Intersect ENT in a report on Friday, April 20th. They set a "buy" rating for the company. Two equity research badysts gave a rating to the stock and ten attributed a purchase grade to the company. The company currently has an average rating of "Buy" and an average price target of $ 38.50.
In addition, Jeryl L. Hilleman sold 12,833 Intersect ENT shares in a transaction dated Tuesday, June 5. The stock was sold at an average price of $ 41.70, for a total value of $ 535,136.10. Following the completion of the transaction, the Chief Financial Officer now holds 36,265 shares of the Company, valued at approximately $ 1,512,250.50. The sale has been disclosed in a document filed with the Securities & Exchange Commission, which is accessible via this link. In addition, Chief Operating Officer Richard E. Kaufman sold 7,000 shares of Intersect ENT in connection with a transaction dated Tuesday, July 10. The shares were sold at an average price of $ 35.02, for a total value of $ 245,140.00. As a result of the closing of the transaction, the Chief Operating Officer now holds 94,512 shares of the Company, valued at approximately $ 3,309,810.24. The disclosure for this sale can be found here. Insiders sold a total of 67,666 shares valued at $ 2,622,476 in the last 90 days. 5.90% of the stock is currently held by insiders of the company.
Intersect Company Profile ENT
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients suffering from conditions of ears, nose and throat in the United States. It offers implants releasing PROPEL and PROPEL mini-drugs for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, an implant releasing steroids to the frontal and maxillary sinus orifices, or openings, dependent sinuses.
Receive News & Ratings for Intersect ENT Daily – Enter your email address below to find the product you are looking for. receive a concise daily summary of the latest news and badyst ratings for Intersect ENT and related companies with MarketBeat.com's free daily newsletter.
Source link
